Blueprint Medicines Corporation

93.08+0.4700+0.51%Vol 365.45K1Y Perf 44.95%
Apr 13th, 2021 16:00 DELAYED
BID93.07 ASK93.18
Open93.12 Previous Close92.61
Pre-Market- After-Market93.08
 - -  - -%
Target Price
105.27 
Analyst Rating
Strong Buy 1.32
Potential %
13.10 
Finscreener Ranking
★★★★★     66.01
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★★     66.94
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     87.33
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap5.39B 
Earnings Rating
Sell
Price Range Ratio 52W %
53.27 
Earnings Date
5th May 2021

Today's Price Range

91.1196.08

52W Range

56.00125.61

5 Year PE Ratio Range

-11.40-16.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-4.55%
1 Month
-13.74%
3 Months
-10.93%
6 Months
-7.59%
1 Year
44.95%
3 Years
-6.44%
5 Years
363.05%
10 Years
-

TickerPriceChg.Chg.%
BPMC93.080.47000.51
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
6.90
7.10
0.05
0.06
-63 864.90
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
100.00
40.10
40.90
-393.40
55.51
RevenueValueIndustryS&P 500US Markets
787.57M
13.59
232.49
89.62
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.57-1.532.55
Q03 20206.4911.1671.96
Q02 2020-2.08-2.28-9.62
Q01 2020-2.15-2.111.86
Q04 2019-1.71-1.3521.05
Q03 2019-2.19-1.9311.87
Q02 2019-1.92-2.04-6.25
Q01 2019-1.83-1.98-8.20
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.72-13.16Negative
6/2021 QR-1.68-8.39Negative
12/2021 FY-6.472.85Positive
12/2022 FY-5.47-7.25Negative
Next Report Date5th May 2021
Estimated EPS Next Report-1.72
Estimates Count8
EPS Growth Next 5 Years %34.00
Volume Overview
Volume365.45K
Shares Outstanding57.96M
Trades Count6.13K
Dollar Volume35.97M
Avg. Volume432.66K
Avg. Weekly Volume318.44K
Avg. Monthly Volume367.08K
Avg. Quarterly Volume416.96K

Blueprint Medicines Corporation (NASDAQ: BPMC) stock closed at 92.61 per share at the end of the most recent trading day (a -1.65% change compared to the prior day closing price) with a volume of 455.17K shares and market capitalization of 5.39B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Blueprint Medicines Corporation CEO is Jeffrey W. Albers.

The one-year performance of Blueprint Medicines Corporation stock is 44.95%, while year-to-date (YTD) performance is -17.42%. BPMC stock has a five-year performance of 363.05%. Its 52-week range is between 56 and 125.61, which gives BPMC stock a 52-week price range ratio of 53.27%

Blueprint Medicines Corporation currently has a PE ratio of 18.20, a price-to-book (PB) ratio of 3.71, a price-to-sale (PS) ratio of 6.82, a price to cashflow ratio of 13.70, a PEG ratio of 2.32, a ROA of 25.22%, a ROC of 32.91% and a ROE of 31.78%. The company’s profit margin is 55.51%, its EBITDA margin is 40.90%, and its revenue ttm is $787.57 Million , which makes it $13.59 revenue per share.

Of the last four earnings reports from Blueprint Medicines Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.72 for the next earnings report. Blueprint Medicines Corporation’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Blueprint Medicines Corporation is Strong Buy (1.32), with a target price of $105.27, which is +13.10% compared to the current price. The earnings rating for Blueprint Medicines Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Blueprint Medicines Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Blueprint Medicines Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 8.05, ATR14 : 5.65, CCI20 : -82.07, Chaikin Money Flow : 0.01, MACD : -1.94, Money Flow Index : 40.81, ROC : -2.22, RSI : 46.32, STOCH (14,3) : 22.62, STOCH RSI : 0.79, UO : 43.69, Williams %R : -77.38), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Blueprint Medicines Corporation in the last 12-months were: Alexis A. Borisy (Option Excercise at a value of $0), Anthony L. Boral (Option Excercise at a value of $634 741), Anthony L. Boral (Sold 40 000 shares of value $3 601 194 ), Ariel Hurley (Option Excercise at a value of $28 952), Ariel Hurley (Sold 9 957 shares of value $936 773 ), Charles A. Rowland (Option Excercise at a value of $307 653), Charles A. Rowland (Sold 20 909 shares of value $2 274 309 ), Christina Rossi (Sold 1 704 shares of value $152 313 ), Christopher K. Murray (Sold 1 210 shares of value $104 984 ), Daniel S. Lynch (Option Excercise at a value of $0), Debra Durso-Bumpus (Option Excercise at a value of $196 410), Debra Durso-Bumpus (Sold 8 393 shares of value $690 036 ), George D. Demetri (Option Excercise at a value of $0), George D. Demetri (Sold 2 462 shares of value $229 850 ), Jeffrey W. Albers (Option Excercise at a value of $704 000), Jeffrey W. Albers (Sold 88 886 shares of value $7 546 255 ), Kathryn Haviland (Option Excercise at a value of $582 653), Kathryn Haviland (Sold 19 838 shares of value $1 934 526 ), Lonnel Coats (Option Excercise at a value of $0), Lynn Seely (Option Excercise at a value of $0), Marion Dorsch (Option Excercise at a value of $964 044), Marion Dorsch (Sold 25 978 shares of value $2 533 400 ), Mark A. Goldberg (Option Excercise at a value of $827 229), Mark A. Goldberg (Sold 32 727 shares of value $3 681 795 ), Michael Landsittel (Sold 1 507 shares of value $130 749 ), Nicholas Lydon (Option Excercise at a value of $0), Nicholas Lydon (Sold 97 413 shares of value $7 953 846 ), Tracey McCain (Sold 1 893 shares of value $164 242 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (78.57 %)
11 (78.57 %)
8 (66.67 %)
Moderate Buy
1 (7.14 %)
1 (7.14 %)
1 (8.33 %)
Hold
2 (14.29 %)
2 (14.29 %)
3 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.32
Strong Buy
1.32
Strong Buy
1.54

Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

CEO: Jeffrey W. Albers

Telephone: +1 617 374-7580

Address: 45 Sidney Street, Cambridge 02139, MA, US

Number of employees: 429

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

67%33%

Bearish Bullish

61%39%

Bearish Bullish

55%45%

News

Stocktwits